ISB News

A Landscape of Pharmacogenomic Interactions in Cancer

The journal Cell published a study today (July 7) about the integrated analysis of drug response in 1,001 cancer cell lines. This study was undertaken by a large international group of researchers including ISB Senior Research Scientist Theo Knijnenburg. The researchers integrated heterogeneous molecular data of 11,215 tumors and 1,001 cell lines in order to study the drug response of these cell lines to 265 anti-cancer drugs. They uncovered numerous oncogenic aberrations that sensitize to an anti-cancer drug. This study is expected to form an important resource to identify therapeutic options for cancer sub-populations.
Read More

Recent Articles

  • COVID-19 Vaccines and Boosters Are Essential for Maternal-Fetal Health

    In light of the recent FDA and CDC decision to approve two updated messenger RNA COVID-19 booster shots, it is imperative to alert the pregnant population of the importance and effectiveness of these vaccines and boosters. 

  • Spotlight on ISB Education graphic

    2022-23 School Year ISB Education Highlights

    From planning, creating and executing workshops for educators to forging new relationships to elevate students, the ISB Education team has been in high gear. Each month throughout the 2022-2023 academic year, we will highlight some of the top projects the team is working on.

  • 2023 ISB Virtual Microbiome Series

    2023 ISB Virtual Microbiome Series Registration Now Open!

    On October 11-13, 2023, ISB will host a virtual course and symposium on how the ecology of our guts protects us from pathogens. Both events are virtual and free. The intended audience for these events are graduate students, postdocs, principal investigators, industry scientists, educators, clinicians, or any other variety of microbiome-curious person from across the globe.